INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 157 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q4 2021. The put-call ratio across all filers is 1.06 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $1,100,871 | +5.4% | 81,971 | -3.0% | 0.00% | – |
| Q4 2022 | $1,044,807 | -16.2% | 84,463 | -5.5% | 0.00% | – |
| Q3 2022 | $1,247,000 | -4.4% | 89,412 | -5.3% | 0.00% | – |
| Q2 2022 | $1,304,000 | -15.1% | 94,376 | 0.0% | 0.00% | – |
| Q1 2022 | $1,536,000 | -1.3% | 94,376 | -1.3% | 0.00% | – |
| Q4 2021 | $1,557,000 | -95.4% | 95,605 | -65.0% | 0.00% | -100.0% |
| Q4 2019 | $33,817,000 | +2080.3% | 272,893 | +1067.6% | 0.01% | – |
| Q3 2019 | $1,551,000 | +10.9% | 23,372 | +32.9% | 0.00% | – |
| Q2 2019 | $1,399,000 | +153.0% | 17,584 | +255.3% | 0.00% | – |
| Q1 2019 | $553,000 | +13.3% | 4,949 | -14.9% | 0.00% | – |
| Q2 2018 | $488,000 | +28.8% | 5,816 | +263.5% | 0.00% | – |
| Q3 2014 | $379,000 | -15.8% | 1,600 | -15.8% | 0.00% | – |
| Q2 2014 | $450,000 | -86.4% | 1,900 | -81.0% | 0.00% | -100.0% |
| Q1 2014 | $3,303,000 | -9.1% | 10,015 | -87.6% | 0.00% | 0.0% |
| Q2 2013 | $3,632,000 | – | 81,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sarissa Capital Management LP | 635,300 | $53,308,000 | 10.69% |
| Senvest Management, LLC | 976,127 | $81,907,000 | 5.65% |
| Melqart Asset Management (UK) Ltd | 390,600 | $32,775,000 | 2.80% |
| Asymmetry Capital Management, L.P. | 25,918 | $2,175,000 | 2.14% |
| Elk Creek Partners, LLC | 386,397 | $32,423,000 | 1.78% |
| BB BIOTECH AG | 545,719 | $45,791,000 | 1.32% |
| ALTRINSIC GLOBAL ADVISORS LLC | 383,166 | $32,151,000 | 1.27% |
| DLD Asset Management, LP | 129,000 | $10,824,000 | 0.82% |
| Opus Point Partners Management, LLC | 3,998 | $335,000 | 0.73% |
| Virtus ETF Advisers LLC | 8,970 | $753,000 | 0.67% |